Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine
出版年份 2017 全文链接
标题
Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine
作者
关键词
-
出版物
Scientific Reports
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-11-03
DOI
10.1038/s41598-017-15172-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Interplay between Fanconi anemia and homologous recombination pathways in genome integrity
- (2016) Johanna Michl et al. EMBO JOURNAL
- The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells
- (2016) Ping Chen et al. CELLULAR ONCOLOGY
- Global Cancer Incidence and Mortality Rates and Trends--An Update
- (2015) L. A. Torre et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives
- (2015) Joan Minguet et al. INTERNATIONAL JOURNAL OF CANCER
- LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models
- (2015) Darlene Barnard et al. INVESTIGATIONAL NEW DRUGS
- ATM and ATR as therapeutic targets in cancer
- (2015) Anika Maria Weber et al. PHARMACOLOGY & THERAPEUTICS
- Molecular Profiling in Non–Small Cell Lung Cancer: A Step Toward Personalized Medicine
- (2013) Kirtee Raparia et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo
- (2013) Ryan Montano et al. BMC CANCER
- The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design
- (2013) Ruth Thompson et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776
- (2013) C. G. Engelke et al. CLINICAL CANCER RESEARCH
- Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer
- (2012) Maurice Pérol et al. JOURNAL OF CLINICAL ONCOLOGY
- The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition
- (2012) Ruth Thompson et al. PLoS One
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- Claspin and Chk1 regulate replication fork stability by different mechanisms
- (2011) Jennifer Scorah et al. CELL CYCLE
- Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase
- (2011) Samuel McNeely et al. CELL CYCLE
- Pathology of Lung Cancer
- (2011) William D. Travis CLINICS IN CHEST MEDICINE
- Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
- (2011) T. J. Guzi et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites
- (2011) R. Montano et al. MOLECULAR CANCER THERAPEUTICS
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
- (2010) Y. Dai et al. CLINICAL CANCER RESEARCH
- Maintaining genome stability at the replication fork
- (2010) Dana Branzei et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
- (2010) Cynthia X. Ma et al. TRENDS IN MOLECULAR MEDICINE
- Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid -amide]
- (2009) A. G. Jobson et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
- (2009) L. A. Parsels et al. MOLECULAR CANCER THERAPEUTICS
- Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy
- (2008) P.H. Clingen et al. BIOCHEMICAL PHARMACOLOGY
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
- (2008) A. Blasina et al. MOLECULAR CANCER THERAPEUTICS
- The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage
- (2008) E M Bahassi et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search